TY - JOUR T1 - Decision support system to evaluate VENTilation in the Acute Respiratory Distress Syndrome (DeVENT study) – Trial Protocol JF - medRxiv DO - 10.1101/2021.08.25.21262610 SP - 2021.08.25.21262610 AU - Brijesh Patel AU - Sharon Mumby AU - Nicholas Johnson AU - Emanuela Falaschetti AU - Jorgen Hansen AU - Ian Adcock AU - Danny McAuley AU - Masao Takata AU - Dan S. Karbing AU - Matthieu Jabaudon AU - Peter Schellengowski AU - Stephen E. Rees AU - On behalf of the DeVENT study group Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/01/2021.08.25.21262610.abstract N2 - Background The Acute Respiratory Distress Syndrome (ARDS) occurs in response to a variety of insults, and mechanical ventilation is life-saving in this setting, but ventilator induced lung injury can also contribute to the morbidity and mortality in the condition. The Beacon Caresystem is a model-based bedside decision support system using mathematical models tuned to the individual patient’s physiology to advise on appropriate ventilator settings. Personalised approaches using individual patient description may be particularly advantageous in complex patients, including those who are difficult to mechanically ventilate and wean, in particular ARDS.Methods We will conduct a multi-centre international randomised, controlled, allocation concealed, open, pragmatic clinical trial to compare mechanical ventilation in ARDS patients following application of the Beacon Caresystem to that of standard routine care to investigate whether use of the system results in a reduction in driving pressure across all severities and phases of ARDS.Discussion Despite 20 years of clinical trial data showing significant improvements in ARDS mortality through mitigation of ventilator induced lung injury, there remains a gap in its personalised application at the bedside. Importantly, the protective effects of higher positive end-expiratory pressure (PEEP) were noted only when there were associated decreases in driving pressure. Hence, the pressures set on the ventilator should be determined by the diseased lungs’ pressure-volume relationship which is often unknown or difficult to determine. Knowledge of extent of recruitable lung could improve the ventilator driving pressure. Hence, personalised management demands the application of mechanical ventilation according to the physiological state of the diseased lung at that time. Hence, there is significant rationale for the development of point-of-care clinical decision support systems which help personalise ventilatory strategy according to the current physiology. Furthermore, the potential for the application of the Beacon Caresystem to facilitate local and remote management of large numbers of ventilated patients (as seen during this COVID-19 pandemic), could change the outcome of mechanically ventilated patients during the course of this and future pandemics.Trial registration ClinicalTrials.gov identifier (NCT number): NCT04115709Administrative information Note: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/).View this table:Competing Interest StatementJH is chief executive officer for Mermaid Care A/S who manufacture the Beacon Caresystem. SR and DK are minor shareholders and SR is a board member of Mermaid Care A/S who manufacture the Beacon Caresystem. Clinical TrialClinicalTrials.gov identifier (NCT number): NCT04115709Funding StatementThe European Commission Horizon 2020 Fast Track to Innovation Programme will be providing the research costs for the DeVENT study (Reference EU project 853850 - ECMO-BIOMARKER). The funder had no role in the trial design, collection, management, analysis or interpretation of data, writing of reports or submission for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In the UK, the study received ethical approval by the London South-East Research Ethics Committee (Ref: 19/LO/1606) on 15 January 2020 with proitocol version 4.0 approved on 16th June 2021. The study protocol was approved by the French Ethics Committee (Comitè de Protection des Personnes Sud Mediterranee III; approved on July 30, 2020 under number2019.12.06 ter_19.11.15.76132) and Medicine Agency (Agence Nationale de Sècuritè du Mèdicament; approved on July 3, 2020 under number 2019-A02610-57-A). The study protocol was approved by the ethics committee of Medical University of Vienna, Austria (EC No. 2056/2019) on 28th April 2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available on request through the sponsor.Abbreviation / AcronymFull WordingABGArterial Blood GasAEAdverse EventALPEAutomatic Lung Parameter EstimationAPACHE IIAcute Physiology and Chronic Health Evaluation Score IIAPMICAnaesthesia, Pain Medicine and Intensive CareAPRVAirway Pressure Release VentilationARDSAcute Respiratory Distress SyndromeBALBronchoalveolar lavageCIChief InvestigatorCO2Carbon DioxideCONSORTConsolidated Standards of Reporting TrialsCOVID-19Novel Coronavirus Disease 2019CRF/eCRFCase Report Form/Electronic Case Report FormCTUClinical Trials UnitDMECData Monitoring and Ethics CommitteeDNARDo Not Attempt ResuscitationECMOExtracorporeal Membrane OxygenationECCO2RExtraCorporeal Carbon Dioxide RemovalEQ-5D-5LEuroQoL-5 Dimension Questionnaire (5 level version)EELVEnd-Expiratory lung VolumeFE’CO2End-tidal CO2 fractionFiO2Fraction of Inspired OxygenGCPGood Clinical PracticeHADSHospital Anxiety and Depression ScoreHRAHealth Research AuthorityHRQoLHealth Related Quality of LifeICFInformed Consent FormICHInternational Council on HarmonisationICTUImperial Clinical Trials UnitICUIntensive Care UnitIRASIntegrated Research Application SystemMHRAMedicines and Healthcare products Regulatory AgencyMOCAThe Montreal Cognitive AssessmentNHSNational Health ServiceNIHRNational Institute for Health ResearchNIVNon Invasive VentilationNMBDNeuromuscular Blocking DrugsPaCO2Partial Pressure of Carbon Dioxide in arterial bloodPaO2Partial Pressure of Oxygen in arterial bloodPBWPredicted Body WeightPEEPPositive End Expiratory PressureP/Fratio PaO2/FiO2 ratioPIPrincipal InvestigatorPISPatient Information SheetPPIPatient and Public InvolvementPplatPlateau PressurePTSDPost Traumatic Stress DisorderPTSS14 Post Traumatic Stress Syndrome QuestionnaireRALERadiographic Assessment of Lung OedemaRECResearch Ethics CommitteeRRRespiratory RateSAESerious Adverse EventSAPStatistical Analysis PlanSAPS IISimplified Acute Physiology ScoreSBTSpontaneous Breathing TrialSGRQSt George’s Respiratory QuestionnaireSOFASequential Organ Failure AssessmentSOPsStandard Operating ProceduresSpO2Oxygen SaturationSRMStudy Reference ManualTAPSETricuspid Annular Plane Systolic ExcursionTIDIeRTemplate for intervention description and replicationTMFTrial Master FileTMGTrial Management GroupTSCTrial Steering CommitteeVCO2Carbon Dioxide productionVILIVentilator Induced Lung InjuryVO2Oxygen ConsumptionVtTidal Volume ER -